Abstract 4849
Background
Endoplasmic reticulum (ER) stress-induced, unfolded protein response (UPR)-mediated apoptosis is a protective mechanism whose failure contributes to malignant tumor progression. XAF1 is a stress-inducible, pro-apoptotic tumor suppressor which is inactivated in many human tumor cells. The molecular signal mechanism explaining its function in controlling ER stress, however, remains largely unclear. In this study, we explored the role of XAF1 in UPR signaling and ER stress-induced apoptosis.
Methods
XAF1 and GRP78 expression were determined by RT-PCR and immunoblot assay. the interplay of XAF1 with GRP78 was defined using immunoprecipitation and in vitro pull-down assays. ER stress was induced using thapsigargin, tunicamycin and brefeldin A. Flow cytometry was used to assess cell cycle progression and apoptosis.
Results
XAF1 expression is upregulated at the transcriptional level in response to ER stress and this activation is abolished by suppression of PERK-Nrf2 but not of IRE1a or ATF6 signaling. This indicates that XAF1 is a target of Nrf2 in transcriptional level and activated by ER stress through the PERK pathway. This XAF1 induction greatly enhances the apoptotic response of tumor cells to ER stress while blockade of XAF1 induction reduces apoptotic sensitivity of tumor cells to ER stress. Intriguingly, XAF1 decreases the protein level of the ER stress sensor, GRP78, and consequently activates UPR signaling. Mechanistically, XAF1 binds directly to GRP78 and stimulates its proteasomal degradation in an E3 ligase ZNF313-dependent manner. XAF1 facilitates ZNF313 interaction with GRP78 and thereby promoting ZNF313-mediated K48 ubiquitination of GRP78. Unlikely wild-type XAF1, mutant XAF1 lacking GRP78- or ZNF313-binding domain shows no activity to promote ER stress-induced apoptosis.
Conclusions
Conclusion: XAF1 sensitizes cells to ER stress and drives apoptotic switch of UPR function away from cell cycle arrest by directly antagonizing GRP78 through the assembly of a ZNF313-mediated destruction complex. Our study identifies first a cell-fate decisions function of XAF1 under ER stress conditions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sung-Gil Chi.
Funding
BK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract